Investment Counsel buys $4,352,619 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Investment Counsel scooped up 1,173 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 18, 2016. The investment management firm now holds a total of 34,782 shares of Johnson & Johnson which is valued at $4,352,619.Johnson & Johnson makes up approximately 3.42% of Investment Counsel’s portfolio.

Other Hedge Funds, Including , Fox Run Management L.l.c. sold out all of its stake in JNJ during the most recent quarter. The investment firm sold 4,700 shares of JNJ which is valued $588,158.Regent Investment Management boosted its stake in JNJ in the latest quarter, The investment management firm added 2,468 additional shares and now holds a total of 43,817 shares of Johnson & Johnson which is valued at $5,395,625. Johnson & Johnson makes up approx 2.82% of Regent Investment Management’s portfolio. Pure Financial Advisors added JNJ to its portfolio by purchasing 2,927 company shares during the most recent quarter which is valued at $360,021. Johnson & Johnson makes up approx 0.12% of Pure Financial Advisors’s portfolio.Grassi Investment Management boosted its stake in JNJ in the latest quarter, The investment management firm added 107 additional shares and now holds a total of 75,678 shares of Johnson & Johnson which is valued at $9,308,394. Johnson & Johnson makes up approx 1.72% of Grassi Investment Management’s portfolio.Lgt Capital Partners Ltd. reduced its stake in JNJ by selling 49,000 shares or 48.61% in the most recent quarter. The Hedge Fund company now holds 51,800 shares of JNJ which is valued at $6,371,400. Johnson & Johnson makes up approx 1.08% of Lgt Capital Partners Ltd.’s portfolio.

Johnson & Johnson closed down -0.11 points or -0.09% at $125.14 with 73,34,633 shares getting traded on Wednesday. Post opening the session at $125.84, the shares hit an intraday low of $125.04 and an intraday high of $126.07 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Leave a Reply

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.